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Collagen I foams are used in the clinic as scaffolds to promote articular carti-
lage repair as they provide a bioactive environment for cells with chondrogenic 
potential. However, collagen I as a base material does not allow for precise con-
trol over bioactivity. Alternatively, recombinant bacterial collagens can be used 
as “blank slate” collagen molecules to offer a versatile platform for incorpora-
tion of selected bioactive sequences and fabrication into 3D scaffolds. Here, we 
show the potential of Streptococcal collagen-like 2 (Scl2) protein foams modified 
with peptides designed to specifically and noncovalently bind hyaluronic acid 
and chondroitin sulfate to improve chondrogenesis of human mesenchymal 
stem cells (hMSCs) compared to collagen I foams. Specific compositions of 
functionalized Scl2 foams lead to improved chondrogenesis compared to both 
nonfunctionalized Scl2 and collagen I foams, as indicated by gene expression, 
extracellular matrix accumulation, and compression moduli. hMSCs cultured in 
functionalized Scl2 foams exhibit decreased collagens I and X gene and protein 
expression, suggesting an advantage over collagen I foams in promoting a 
chondrocytic phenotype. These highly modular foams can be further modified 
to improve specific aspects chondrogenesis. As such, these scaffolds also have 
the potential to be tailored for other regenerative medicine applications.
contributes to load transmission to the 
underlying subchondral bone.[2] The 
unique biochemical microenvironment 
of articular cartilage is intimately linked 
with the biological function of the tissue 
and cell-regulated homeostasis.[3] While 
articular cartilage can perform these self-
regulating functions throughout the life 
of a healthy individual, trauma and/or 
disease leads to alterations in this envi-
ronment and causes progressive degen-
eration of the tissue.[1–3] This process is 
made worse by articular cartilage’s limited 
capacity for self-repair and regeneration, 
which is partly due to its avascular and 
aneural nature and the inability of resident 
cells to migrate to the site of injury.[4,5]
A number of treatments have been 
developed to manage the symptoms of 
cartilage damage and stimulate articular 
cartilage repair and/or regeneration. 
These can be divided into two main cat-
egories: (1) nonsurgical approaches such 
as nonsteroidal anti-inflammatory drugs 
(NSAIDs),[6] weight loss/joint strengthening, as well as visco-
supplementation,[7] and (2) surgical interventions including 
microfracture,[8] autologous chondrocyte implantation (ACI),[5] 
mosaicplasty,[1,3] and periosteal transplantation.[9] Cell-based 
therapies often deliver short-term recovery in joint mobility 
and pain relief to patients, but the long-term benefits remain 
elusive.[10] This is often attributed to the quality of the repair 
tissue, which does not exhibit the same biomechanical com-
position, organization, and associated mechanical behavior as 
that of the native tissue, eventually leading to degeneration and 
failure of the repair tissue. In recent years, significant efforts 
have been made to improve the outcome of these cell-based 
strategies through tissue engineering principles.[11–15] Notably, 
a number of scaffolds have been developed to improve the 
outcome of ACI and microfracture approaches. These tech-
niques are referred to as matrix-induced autologous chondro-
cyte implantation (MACI).[16–21] Currently, there are several dif-
ferent types of scaffolds used for MACI in clinical settings that 
are based on hyaluronic acid (HA) (Hyalograft C),[22] collagen-
chondroitin sulfate (CS) (Novocart),[23] fibrin combined with 
polyglycolic/polylactic acid and polydioxanone (Bioseed C),[24]  
1. Introduction
Articular cartilage is a highly complex and dynamic connec-
tive tissue that covers the surfaces of bones in synovial joints,[1] 
where it provides a low-friction, wear-resistant surface and 
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agarose–alginate (Cartipatch),[25] or collagen type I.[17] Col-
lagen-based scaffolds are most commonly employed for MACI 
because they have been shown to stimulate the synthesis of 
glycosaminoglycans (GAGs) and collagen type II,[26,27] the two 
main extracellular matrix (ECM) components in articular car-
tilage.[28,29] Collagen type I foams in particular have been used 
extensively because of their biocompatibility and hydrophilic 
nature.[30–36] Furthermore, collagen type I foams have inherent 
bioactivity and cell biorecognition features, which are reported 
as advantageous. However, collagen type I is not the major col-
lagenous component of articular cartilage matrix and as such 
may contain bioactive sites that do not facilitate chondrogen-
esis. A number of studies have also demonstrated a loss of 
chondrogenic phenotype in resident cells within collagen type 
I-based scaffolds over a prolonged culture period, leading to the 
eventual upregulation of hypertrophic markers.[22,34,37]
Recently, recombinantly synthesized bacterial proteins, such 
as Streptococcus collagen-like 2 (Scl2) protein found on the cell 
surface of Streptoccocus pyogenes,[38] have been investigated for 
their potential use in tissue engineering applications.[34,39] Sim-
ilar to mammalian collagens, Scl2 proteins are characterized 
by a triple helical conformation consisting of the characteristic 
repeating (Gly–Xaa–Yaa)n units.[34,40,41] Interestingly, Scl2 pro-
teins do not contain cell-binding or bioactive sequences within 
their backbone and thus effectively offer a biologically “blank 
collagen template” onto which modifications can be made to 
systematically integrate carefully selected biological sequences 
to direct specific cell behavior.[42] Scl2 proteins offer an alterna-
tive to mammalian type I collagen because they do not require 
post-translational modification and exhibit minimal batch-to-
batch variation in quality, predictability of performance, and 
purity. These proteins have also been shown to be noncyto-
toxic and nonimmunogenic.[41,42] Thus, Scl2 proteins offer the 
opportunity to tailor functionality to manipulate specific cel-
lular responses. The incorporation of bioactive moieties can 
be achieved either by tethering from the backbone[43] or inte-
grating the peptide sequence within the collagen backbone via 
site-directed mutagenesis during Scl2 production,[42] making 
Scl2 proteins an advantageous alternative to collagen type I for 
scaffold fabrication.
In this work, we developed porous foams based on these 
recombinant Scl2 proteins with peptide sequences incorporated 
in the backbone that specifically bind HA or CS. GAGs such as 
HA and CS are abundantly present in the native cartilage ECM 
and are known to play significant roles in a variety of cell–ECM, 
cell–cell, and protein interactions.[44,45] Their presence in native 
articular cartilage is particularly important for tissue mechanics 
and biological function. Our group has recently shown that 
the HA-binding and CS-binding peptides can specifically and 
dynamically bind HA and CS within a single scaffold, mim-
icking the dynamic nature of the ECM.[44,45] In this work, we 
demonstrate the potential of Scl2 protein foams containing var-
ying ratios of GAG-binding peptides to modulate an improved 
chondrogenic response by human mesenchymal stem cells 
(hMSCs) compared to collagen type I foams. These highly ver-
satile foams can be further modified through the incorporation 
of additional bioactivity to the Scl2 backbone to finely tune the 
cellular response and recapitulate the complexity of the native 
microenvironment. As such, these scaffolds have the potential 
to also be adapted for other applications in regenerative medi-
cine and tissue engineering.
2. Results and Discussion
2.1. Characterization of Collagen Foams
2.1.1. Morphological Characterization
Collagen foams were prepared with blank Scl2, HA-Scl2, 
CS-Scl2, mixtures of HA-Scl2 and CS-Scl2, and collagen type 
I, and then imaged using scanning electron microscopy (SEM) 
and multiphoton second harmonic generation (MP-SHG) 
(Figure 1, Figure S1, and Figure S2, Supporting Information). 
No differences in morphology were observed between the dif-
ferent types of foams including those made with collagen type 
I versus Scl2. Additionally, FTIR spectroscopy (Figure S3, Sup-
porting Information) confirmed no identifiable differences 
between all collagen foams. A characteristic IR transmittance 
peak at 1630 cm−1 (amide C O) was present in all samples. 
All foams were subjected to a dehydrothermal crosslinking 
treatment, whereby the resultant intermolecular crosslinks 
formed via condensation reactions likely locked in the col-
lagen molecules resulting in the observed morphologies.[46–48] 
Multiple studies have shown that the majority of the collagen 
molecules maintain their triple helical conformation under 
the crosslinking conditions used in the present study. Previous 
studies have also demonstrated the presence of a triple helix in 
Scl2 molecules that have been modified to incorporate integrin-
binding or heparin-binding domains in the backbone.[39,42]
2.1.2. Mechanical Characterization
For all foams, the collagen concentration and crosslinking treat-
ment were kept constant to produce structures with similar 
mechanical properties to facilitate appropriate comparison 
of cellular response on the different foam compositions.[49–51] 
The compression moduli of the foams were determined using 
unconfined DMA and found to range between ≈2.9–3.6 kPa 
at 1 Hz (Figure S4, Supporting Information). There were no 
statistical differences between compression moduli of the dif-
ferent bacterial collagen and collagen type I foam formulations. 
The foams also exhibited increased compression moduli with 
increasing frequency from 0.1 Hz (≈1.1–1.8 kPa) to 10 Hz 
(≈5.5–6.2 kPa).
2.1.3. GAG-Binding and Swelling Behavior
Bacterial collagen proteins containing HA-binding and CS-
binding sequences demonstrated specific binding to HA and 
CS, respectively (Figure 2A,B), compared to the blank Scl2 con-
trol and proteins functionalized with a different binding moiety. 
Interestingly, no significant differences were measured in HA 
and CS binding between the collagen type I proteins and the 
HA-Scl2 and CS-Scl2 proteins, respectively. Collagen type I 
is not known to contain reported HA- or CS-specific binding 
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sequences, which suggests that the significant amount of HA 
and CS binding was due to nonspecific binding, most likely 
through interactions with other interactive moieties present 
on collagen type I rather than charge effects caused by the 
collagen type I and Scl2 molecules.[30–32] At a neutral pH, the 
amino acids present on collagen type I molecules are known 
to have a net charge close to the isoelectric point.[52,53] For this 
reason, it is unlikely that HA and CS, highly negatively charged 
molecules, would bind to the collagen type I molecules through 
charge effects alone. A small amount of nonspecific GAG 
binding to the bacterial collagen proteins was also observed on 
the HA-Scl2 and CS-Scl2 proteins; however, this binding was 
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Figure 1. Schematic diagrams of Streptococcal collagen-like 2 (Scl2) protein constructs containing A) HA-binding and B) CS-binding peptide sequences. 
The “CPPC” domains represent the amino acid sequences inserted at the N and C termini to enhance stability of each construct. Collagen foams mor-
phology. Representative SEM images of C) collagen type I and E) Scl2 foams (scale bars are 100 μm). Representative MP–SHG images of D) collagen 
type I and F) Scl2 foams (scale bars are 200 μm). Insets show photographs of collagen foams of 8 mm in diameter.
Figure 2. GAG binding on collagen foams. Binding of fluorescently labeled A) HA and B) CS to bacterial collagen and collagen type I foams. Empty 
wells were used as negative control denoted “no material.” Release of fluorescently labeled C) HA and D) CS from collagen foams over 1 week. Swelling 
behavior of collagen foams after preincubation with E) HA and F) CS expressed as a percentage of the swelling of collagen foams without HA and CS. 
Values represent means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 (n = 3).
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not significant compared to the blank Scl2 protein. Importantly, 
specific GAG binding could be modulated by controlling the 
relative ratio of the HA-binding to CS-binding peptides, which 
allows an element of control to the design of bacterial collagen 
foams that is not possible with collagen type I foams. Moreover, 
the HA-Scl2 and CS-Scl2 foams exhibited comparable binding 
and release of HA and CS with the collagen type I foams 
(Figure 2C,D), respectively. The binding and release of GAGs 
are likely to be a dynamic process during culture.
Collagen type I and bacterial collagen foams containing HA-
binding and/or CS-binding peptides swelled significantly more 
than the blank Scl2 foams following a 48 h incubation with 
HA or CS compared to incubation in PBS without exogenous 
GAGs (Figure 2E,F). These results are in agreement with the 
GAG-binding findings (Figure 2A,D) as GAGs are known to 
draw in significant amounts of water.[43,54,55] Interestingly, in 
the absence of HA or CS, all bacterial collagen foams swelled 
significantly more than the collagen type I foam at 48 h with 
the exception of the blank Scl2 foams (Figure S5, Supporting 
Information). As the swelling behavior of the each foam rep-
resents its increase in size, it is likely a reflection of a change 
at the structural level. As expected, MP–SHG images of all 
functionalized foams and collagen type I foams demonstrated 
an expected increase in pore size following incubation with HA 
or CS compared to the blank Scl2 foams (Figure S2H–U, Sup-
porting Information).
2.1.4. Degradation Kinetics
All foams displayed minimal weight change (less than 10%) 
over 6 weeks in medium (Figure 3A). The physical crosslinks 
interlocking the collagen molecules in the foams likely held the 
structure together. After incubation with enzymes known to 
be secreted during chondrogenesis of hMSCs (MMP1, MMP2, 
MMP7, or MMP13)[43,50,56] a significantly increased weight 
change of the foams was observed compared to medium alone 
over 6 weeks (Figure 3B). This is likely because MMPs can be 
promiscuous and are known to recognize and cleave a range 
of amino acid sequences.[50,56–58] The bacterial collagen foams 
had a weight reduction of ≈15.2%–23.4% over 6 weeks in the 
presence of MMPs. Interestingly, the collagen type I foams had 
a weight reduction of ≈34.6%–41.8% depending on the MMP 
treatment. It is not surprising that the collagen type I foams 
degraded faster than those made of bacterial collagen because 
bacterial collagens are not designed to contain known enzyme-
specific cleavage sites while collagen type I has multiple 
enzymatically targeted sites.[34,41–43] We postulate that these 
observations may translate positively to the in vivo environ-
ment, where a slower degradation rate of the bacterial collagen 
foams might represent an advantage in allowing increased time 
for guided matrix accumulation and reorganization compared 
to collagen type I foams.[43,50,59–61] It is also possible to incorpo-
rate specific MMP-cleavable peptide sequences within the Scl2 
backbone to tune the degradation of the foams.[43,50,56]
2.2. Cellular Response to Collagen Foams
2.2.1. Cell Adhesion and Viability
The metabolic activity and DNA content of hMSCs were main-
tained at high levels in all foams and increased throughout 
the culture period in all conditions with the exception of the 
metabolic activity of hMSCs cultured in blank Scl2 foams 
(Figure 4). The metabolic activity and DNA content of hMSCs 
were not significantly different between the collagen type I 
foams and bacterial collagen foams incorporating HA-binding 
and/or CS-binding sequences at all-time points. Additionally, 
there was no exogenous supply of GAGs during in vitro cul-
ture and thus, metabolic activity of hMSCs was measured in 
the presence of an endogenous supply of GAGs. The blank Scl2 
foams, however, did have a lower metabolic activity and DNA 
content at day 42 compared to the collagen type I foams. The 
difference between collagen type I and blank Scl2 foams may 
be explained by the bioactive sites present in the collagen type 
I backbone, including integrin-binding sites.[43,44,62–66] Such 
bioactive sites are not present in the blank Scl2 foams and 
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Figure 3. Degradation profile of acellular collagen foams. Degradation of collagen foams incubated in A) chondrogenic medium and B) chondrogenic 
medium supplemented with recombinant human MMP1, 2, 7, or 13 (30 ng mL−1) over time characterized as dry weight loss and expressed as a per-
centage of initial dry weight. Proteinase K-driven degradation is used as a positive control. Chondrogenic medium without exogenous enzymes is used 
as a negative control. Values represent means ± SD (n = 3).
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therefore, additional selected bioactivity has been programmed 
into the blank Scl2 backbone via the incorporation of the GAG-
binding peptides, demonstrating a high degree of control and 
modularity over the collagen type I foams. The HA-binding 
and/or CS-binding sequences used in this study have previ-
ously been shown to improve cell viability and impact biological 
processes.[43] The goal of the bacterial collagen is to provide 
an interface for the retention of GAGs produced by the cells. 
Our results suggest that this is sufficient to encourage cells to 
populate the functionalized foams. Cell viability in the different 
foams was further confirmed by a LIVE/DEAD assay at day 42 
(Figure S6, Supporting Information).
2.2.2. In Vitro Chondrogenesis
The ability to modulate the chondrogenic differentiation of 
hMSCs seeded within Scl2 foams functionalized with HA-
binding and/or CS-binding peptides was evaluated compared 
to the collagen type I and blank Scl2 foams.[43,44,62] The gene 
expression of chondrogenic markers (COL2A1, ACAN, and 
SOX9) (Figure 5A–C) indicated that collagen type I foams sig-
nificantly enhanced chondrogenic differentiation of hMSCs at 
an early time point (week 1) compared to the blank Scl2 foams. 
Furthermore, COL2A1 and SOX9 gene expression by hMSCs 
in the collagen type I foams were significantly upregulated 
compared to other functionalized Scl2 foams at week 1. How-
ever, the expression profiles of all three chondrogenic marker 
genes plateaued from week 2 to week 6 for hMSCs seeded in 
collagen type I foams at which point COL2A1 gene expression 
of cells in the collagen type I foams was not significantly dif-
ferent to that of cells in the blank Scl2 foams. Interestingly, 
hMSCs in the HA:CS(75:25)-Scl2 foams had significantly 
higher COL2A1, ACAN, and SOX9 gene expression at all-time 
points from week 2 onwards compared to those in the col-
lagen type I foams. Similarly, significantly higher expression of 
the chondrogenic marker genes was also observed compared 
to hMSCs in the HA-Scl2 foams at week 2 and week 4. HA-
binding and CS-binding peptides incorporated in the bacterial 
collagen molecules displayed different extents of chondrogenic 
differentiation of hMSCs despite their similar charge. It has 
previously been shown that the GAG-binding peptides selected 
in this study can be used to dynamically and spatially organize 
the GAG molecules in the same system, suggesting that these 
peptides interact with endogenous GAG molecules via specific 
peptide–GAG interactions rather than electrostatic interac-
tions.[43,44] The HA-binding peptide sequence is derived from 
a HA-binding region of the link protein involved in the sta-
bilization of interactions between HA and aggrecan in native 
articular cartilage[44] and has been shown to significantly pro-
mote the chondrogenesis of hMSCs.[43] The CS-binding peptide 
sequence is derived through phage display and has previously 
been shown to noncovalently and specifically bind CS. It is pos-
sible that the combination of the HA-binding and CS-binding 
peptides led to a positive synergistic effect on cell behavior by 
mimicking native-like protein–GAG interactions. hMSCs in 
the HA-Scl2 foams exhibited significantly higher COL2A1 and 
ACAN gene expression at all-time points, and SOX9 at week 2 
to week 6 compared to those seeded in the CS-Scl2 foams.
Gene expression levels of COL1A1 and COL10A1 
(Figure 5D,E) were significantly higher for hMSCs seeded 
in blank Scl2 and collagen type I foams compared to all 
other foams at week 6. Furthermore, COL1A1 and COL10A1 
gene expression by hMSCs in these two types of foams 
were upregulated unlike all other foam formulations, where 
they remained at basal levels or were downregulated. These 
results suggest that a controlled functionalization approach 
through the use of selected modifications to Scl2 delayed or 
inhibited terminal differentiation of hMSCs. Terminal chon-
drocyte differentiation of hMSCs toward a hypertrophic state 
is a critical challenge in cartilage tissue engineering as it 
can lead to calcification of the newly deposited tissue.[43,67,68] 
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Figure 4. Metabolic activity and DNA content of hMSCs cultured in collagen foams. A) hMSC metabolic activity in collagen foams over 6 weeks in 
culture. B) DNA content of hMSCs per construct in collagen foams over 6 weeks in culture. All data normalized to day 0. Values represent means ± 
SD (n = 3 for each donor; 3 different bone marrow-derived hMSC donors).
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COL2A1/COL1A1 gene expression ratio for the HA-Scl2 and 
HA:CS(75:25)-Scl2 foams remained high compared to the 
blank Scl2 and collagen type I foams over 6 weeks of culture 
(Figure 5F), possibly limiting the fibrochondrocyte phenotype, 
which is also problematic for the long-term outlook of carti-
lage repair.[1,3,62,63] Collagen type I has multiple biological moi-
eties including integrin-binding sites that may be interfering 
with the extent of chondrogenesis and promoting terminal 
differentiation and fibrochondrocyte phenotype compared to 
HA-Scl2 and HA:CS(75:25)-Scl2 foams.[43,44,69] Our results 
indicate that this is a consequence of both an upregulation 
of collagen type II and a downregulation of collagen type I 
gene expression by hMSCs in the functionalized foams com-
pared to the blank Scl2 and collagen type I foams. Based on 
previous findings,[43] we do believe that the GAG-binding pep-
tides contribute to this effect as elaborated in more details in 
that study. However, we also think that this positive effect is a 
response to the absence of bioactive motifs in functionalized 
Scl2 molecules that are not specific to chondrogenesis and are 
present in collagen type I. This is a major advantage of our 
system as we have the ability to incorporate only selected bio-
active molecules.
The hMSC-seeded foams cultured for 6 weeks were further 
analyzed for ECM accumulation. sGAG content normalized to 
DNA (Figure 6A) was significantly higher for the HA-Scl2 and 
HA:CS(75:25)-Scl2 foams compared to the blank Scl2 and col-
lagen type I foams at week 6. Total collagen content normalized 
to DNA (Figure 6B) was also significantly higher for the 
HA-Scl2 and HA:CS(75:25)-Scl2 foams compared to the blank 
Scl2 foams at week 6. Total collagen was not assessed for col-
lagen type I foams because the foams contain hydroxyproline, 
unlike Scl2, which would have biased the results. These results 
further validated the benefit of tunable Scl2 proteins as a base 
material to engineer foams that elicit specific cell-modulating 
behavior compared to collagen type I foams currently used in 
the clinic. The increased ECM accumulation also translated to 
higher compression moduli for the HA-Scl2 and HA:CS(75:25)-
Scl2 foams compared to the blank Scl2 and collagen type I 
foams (Figure 6C and Figure S7, Supporting Information). 
Similarly, all foam formulations gained weight throughout the 
culture period, suggesting that ECM accumulation occurred at a 
faster rate than foam degradation (Figure S8, Supporting Infor-
mation). Histological evaluation of the foams demonstrated a 
homogeneous distribution of cells and ECM for all foam types 
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Figure 5. hMSC gene expression in collagen foams. A) COL2A1, B) ACAN, C) SOX9, D) COL1A1, and E) COL10A1 gene expression of hMSCs seeded 
in collagen foams over 6 weeks in culture, as analyzed using the ΔΔCt method. Data presented as a fold difference relative to undifferentiated hMSCs 
(calibrator) prior to seeding and normalized to GAPDH (housekeeping gene). F) COL2A1/COL1A1 gene expression ratio. Values represent means ± 
SD. *p < 0.05, **p < 0.01, ***p < 0.001 (n = 3 for each donor; 3 different bone marrow-derived hMSC donors).
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after 6 weeks in culture (Figure 6D). Extensive sGAG accumula-
tion (Alcian Blue staining) was highly noticeable in the HA-Scl2 
and HA:CS(75:25)-Scl2 foams. Immunohistochemical analysis 
of collagen type II and aggrecan confirmed the gene expres-
sion results (Figure 6D) for all foams. In fact, collagen type II 
and aggrecan stainings were markedly greater in the HA-Scl2 
and HA:CS(75:25)-Scl2 foams compared to the blank Scl2 and 
collagen type I foams. Staining for collagen type I and collagen 
type X (Figure 6D) also confirmed the gene expression profiles 
for all foam formulations. Specifically, staining for collagen 
type I and collagen type X in collagen type I foams was much 
greater compared to the HA-Scl2 and HA:CS(75:25)-Scl2 foams.
2.2.3. Cell–Foam Interactions
Interestingly, GAG-binding results showed that the HA-Scl2, 
HA:CS(75:25)-Scl2, and collagen type I foams all exhibited 
similar levels of HA binding (Figure 2A); however, the extent 
of chondrogenesis of hMSCs seeded within these bacterial 
collagen foams was significantly different to the collagen type I 
foams (Figure 5 and Figure 6). It is unclear whether this effect 
is due to additional bioactive moieties present on collagen type 
I molecules or to the biomimetic interactions between HA and 
the HA-binding peptide selected for this study. To investigate 
the role of HA binding, we assessed the expression of CD44, 
a known HA-binding cell surface receptor.[70–72] CD44 expres-
sion has been associated with inflammation and has been 
shown to negatively impact chondrogenesis when expressed 
at high levels.[73,74] hMSCs in the collagen type I foams had 
significantly higher CD44 gene expression levels compared to 
those in the HA-Scl2 and HA:CS(75:25)-Scl2 foams throughout 
the culture period (Figure 7A). Immunohistochemical analysis 
of CD44 correlated with the CD44 gene expression results 
for all foams (Figure 7B). Additional immunohistochemical 
analysis confirmed the presence of HA in all foams (Figure S9, 
Supporting Information) and correlated with Figure S6 (Sup-
porting Information). It is not possible to infer the contribu-
tion of the specific and biomimetic interaction between HA 
and the HA-binding peptide on chondrogenesis from these 
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Figure 6. ECM accumulation and compressive modulus of hMSC-seeded collagen foams after 6 weeks of culture. A) Sulfated glycosaminoglycan 
(sGAG) content of tissue deposited by hMSCs in collagen foams after 6 weeks in culture. B) Hydroxyproline content of tissue deposited by hMSCs 
in collagen foams after 6 weeks in culture as an estimation of total collagen content. C) Dynamic mechanical analysis (DMA) used to determine the 
elastic modulus of compression of hMSC-seeded collagen foams compressed to 10% strain at 0.5% strain min−1 and 1 Hz after 6 weeks in culture. 
Values represent means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 (n = 3 for each donor; 3 different bone marrow-derived hMSC donors). D) Repre-
sentative histological and immunohistochemical examination of hMSC-seeded collagen foams after 6 weeks in culture. Collagen foams are stained with 
hematoxylin and eosin (H&E), alcian blue for sGAG, and by immunohistochemistry for collagen type I, collagen type II, collagen type X, and aggrecan, 
from top to bottom. Scale bars are 25 μm.
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results on CD44 expression. However, these results do sug-
gest that this specific binding interaction may elicit a different 
cell response than that produced by nonspecific binding with 
collagen type I. The CD44 gene expression levels present in 
the HA:CS(75:25)-Scl2 foams were lower compared to the 
HA-Scl2 foams. This could possibly be due to endogenous CS 
in the HA:CS(75:25)-Scl2 foams interfering with native HA–
CD44 interactions.[70–73] Interestingly, these results also corre-
late with higher chondrogenic marker gene expression levels 
by hMSCs in the HA:CS(75:25)-Scl2 foams compared to the 
HA-Scl2 foams.
3. Conclusion
In this work, we have designed and synthesized novel highly 
porous foams based on recombinant bacterial collagen-mimetic 
proteins that can be easily and specifically tuned to recreate the 
complex biochemical microenvironment of native articular car-
tilage and encourage regeneration. The backbone of blank slate 
bacterial collagen was modified with varying ratios of specific 
HA-binding and/or CS-binding sequences and processed to 
form foams by lyophilization, and dehydrothermal crosslinking. 
The addition of GAG-binding peptides significantly promoted 
the chondrogenesis of hMSCs in the bacterial collagen foams 
compared to blank Scl2 and collagen type I foams. Specifically, 
hMSCs in the HA-Scl2 and HA:CS(75:25)-Scl2 foams had sig-
nificantly higher COL2A1, ACAN, and SOX9 gene expression 
from week 2 onwards resulting in the greatest sGAG and total 
collagen accumulation and increased compression moduli com-
pared to the collagen type I foams. Taken together, these results 
demonstrate the high degree of versatility of bacterial collagen 
foams compared to collagen type I foams and highlight the 
potential of introducing multiple specific binding sequences 
within a single system to promote targeted cellular processes. 
Our novel bacterial collagen system provides a universal 
platform that can be easily adapted for other regenerative medi-
cine and tissue engineering applications.
4. Experimental Section
Materials: All primary and secondary antibodies used for 
immunohistochemistry were purchased from Abcam (UK). All other 
chemicals were purchased from Sigma–Aldrich (UK). All chemicals were 
used as provided by the manufacturers.
Streptoccocal Collagen–Like 2 Protein Synthesis and Purification: The 
gene constructs used were based on the DNA sequence for the fragment 
of the Scl2.28 allele (Q8RLX7) of Streptococcus pyogenes encoding the 
combined globular and collagen-like portions of the Scl2.28 protein, 
but lacking the N and C termini attachment domains as previously 
described.[40–42,45] Constructs included an additional enzyme cleavage 
and spacer sequence LVPRGSP between the N terminal globular 
domain (V) and the following (Gly–Xaa–Yaa)n collagen-like (CL) domain 
sequences. The Scl2 (VCL) construct used as a control was as previously 
described.[40–42,45] The other two constructs contained HA-binding 
(RYPISRPRKR) or CS-binding (YKTNFRRYYRF) peptides integrated in 
the structure. These constructs (HA-Scl2 and CS-Scl2) comprised two 
CL domains with the peptide sequences inserted between the domains 
(Figure 1). The C terminal of these constructs had an additional 
GGPCPPC sequence. Subsequently, in order to further stabilize the 
triple helix an additional GGPCPPC sequence was also added at the N 
terminal between the spacer sequence and the CL domain, using the 
QuikChange site-directed mutagenesis kit (Stratagene) according to 
the manufacturers’ instructions and synthesised primers (Integrated 
DNA Technologies). All DNA sequences were synthesized commercially 
with codon optimization for expression in E. coli (GeneArt Gene 
Synthesis, Germany). The sequences of all constructs were confirmed by 
sequencing prior to transformation and protein expression.
DNA sequences were subcloned into the pColdI (Takara Bio, Japan) 
vector systems for expression in E.coli. The constructs did not include 
an N terminal His6-tag, which was provided by the pColdI vector.[40–42] 
For protein production, a selected positive clone was transformed and 
then expanded in flask culture. The pColdIII constructs were expressed in 
E. coli BL21-DE3 strain. Cells were grown in 2 x yeast extract-tryptone (YT) 
media with ampicillin (100 μg mL−1) at 37 °C, shaking at 200 rpm until the 
A600 absorbance reading reached an optical density in the range 3–6 A.U. 
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Figure 7. CD44 gene expression in hMSCs cultured in collagen foams. A) CD44 gene expression by hMSCs cultured in collagen foams over 6 weeks, as 
analyzed using the ΔΔCt method. Data presented as a fold difference relative to undifferentiated hMSCs (calibrator) prior to seeding and normalized 
to GAPDH (housekeeping gene). Values represent means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 (n = 3 for each donor; 3 different bone marrow-
derived hMSC donors). B) Immunohistochemical examination of tissues in collagen foams for CD44 after 6 weeks of culture. Scale bars are 25 μm.
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Cells were then cooled to 25 °C and isopropyl β-d-thiogalactopyranoside 
(1 × 10−3 m) was added to induce protein expression. After 10 h 
incubation, cells were further cooled to 15 °C for 14 h, after which the 
cells were harvested by centrifugation (12 000 g, 60 min) at 4 °C. For 
protein extraction, cell paste (1 g) was resuspended in sodium phosphate 
buffer (20 mL, 20 × 10−3 m) at pH 8.0 and the cells ruptured using either a 
French press or by sonication on ice, using a Misonix S4000 instrument, 
with a Enhance Booster #1 probe.[40–42,45] Clarified lysate (12 000 g for 
30 min, 4 °C) was adjusted to pH 2.2 and held at 4 °C for 16 h. Any 
precipitate that had formed was removed (12 000 g for 30 min, 4 °C) 
and the supernatant, containing the expressed collagens, was treated by 
pepsin (0.01 mg mL−1) for 16 h at 4 °C.[45] Collagens were concentrated 
and buffer exchanged into sodium phosphate buffer (20 × 10−3 m), pH 
8.0 using a 10 kDa cross-flow filtration membrane (Pall Life Sciences). 
Purity was verified by 12% sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (SDS–PAGE)[40–42] and matrix assisted laser desorption 
spectroscopy (MALDI; Waters).
Preparation of Foams: To generate foams, all protein samples 
were dissolved in acetic acid (10 mg mL−1, 50 × 10−3 m) at room 
temperature, and the pH was adjusted to 7.4 using NaOH (1 m). To 
generate HA:CS(75:25)-Scl2, HA:CS(50:50)-Scl2, and HA:CS(25:75)-Scl2 
foams, HA-Scl2 and CS-Scl2 proteins were mixed in a 75:25, 50:50, and 
25:75 molar ratio, respectively. Blank Scl2 and rat tail collagen type 
I proteins were used as controls. The solutions were sterile-filtered 
and pipetted into 8 mm diameter by 2 mm thickness custom-made 
polydimethylsiloxane molds. The samples were frozen at −20 °C for 
24 h, transferred to −80 °C for 4 h, and lyophilized for 8 h. The samples 
were then subjected to a dehydrothermal cross-linking treatment where 
they were heated to 121 °C for 24 h under high vacuum conditions to 
minimize protein denaturation.[46–48] During the dehydrothermal cross-
linking treatment, water was removed between the collagen molecules 
resulting in the formation of physical intermolecular cross-links through 
condensation reactions via amide formation or esterification. Foams 
were sterilized by washing three times with 70% (v/v) ethanol for 20 min 
each followed by three washes with phosphate buffered saline (PBS) for 
20 min each.
Morphological Characterization: Cross-sectional morphological 
examination of all foams in a dry state was performed. Foams were 
imaged by scanning electron microscopy (SEM) using a JEOL 5610 
(Herts, UK). Samples were coated with 100 Å Au using an Emitech K550 
sputter coater prior to imaging at an accelerating voltage of 15 kV and a 
working distance of 150 mm.
Foams were incubated in PBS, 0.5 mg mL−1 HA (Creative PEGWorks, 
UK), or 0.5 mg mL−1 CS (Creative PEGWorks, UK) for 24 h at 37 °C in a 5% 
CO2 atmosphere, washed three times in PBS and imaged by multiphoton 
second harmonic generation (MP–SHG) in wet state using a Leica SP5 
inverted microscope equipped with a MaiTai HP DeepSee multiphoton 
laser (Spectraphysics) on a 25× NA objective. Second harmonic signal 
was generated at 900 nm and detected on a photomultiplier tube (PMT) 
(435–465 nm). Collagen samples were further characterized using 
Fourier transform infrared (FTIR) spectroscopy. FTIR analysis with a 
PerkinElmer Spectrum One spectrometer was used to determine FTIR 
spectra showing characteristic peaks for all samples. FTIR spectra were 
taken with a scanning wavenumber range from 4000 to 650 cm−1.
Mechanical Characterization: Mechanical properties of the foams 
were studied using dynamic mechanical analysis (DMA) in unconfined 
compression mode. For all tests, samples were incubated in PBS for 
30 min prior to testing and dimensions were measured in wet state using 
digital calipers. Foams were mechanically tested in compression using 
a Bose Electroforce testing machine equipped with a 22.5 N load cell. 
Samples were incubated in PBS, preloaded to 0.05 N, compressed to 
10% strain at a crosshead speed of 0.5% strain min−1, and then followed 
by a frequency sweep from 0.1 to 10 Hz. The compressive modulus was 
calculated from the linear portion of the stress–strain curve.
GAG Binding: The effectiveness at binding and retaining specific 
GAGs on the HA-binding and the CS-binding peptide sequences that had 
been incorporated in the Scl2 backbone was evaluated using fluorescein 
isothiocyanate (FITC)-labeled HA and CS (Creative PEGWorks, UK). 
Scl2 and collagen type I proteins were coated onto 96-well plates, 
incubated at 37 °C for 24 h, washed three times in PBS, incubated in 
bovine serum albumin (BSA) (1% (w/v)) in PBS for 5 h, washed three 
times in PBS, incubated in FITC-labeled HA or CS (0.5 mg mL−1) in PBS 
for 24 h, washed three times in PBS to remove unbound fluorescent 
GAGs, and stored in PBS at 37 °C between measurements. To study 
the release of HA or CS from the foams, foams were processed exactly 
as protein-coated wells. After 1, 3, and 7 d, PBS was removed and 
fluorescence intensities of the supernatant were measured to evaluate 
GAG binding and retention. Samples were excited at 485 or 535 nm, 
and the fluorescence emission intensity was measured at 525 or 620 nm 
for FITC-labeled HA or CS, respectively. Samples were incubated in 
fresh PBS at 37 °C between readings. The fluorescence was measured 
in arbitrary units and relative binding of HA or CS was normalized to 
the highest level of fluorescent intensity at each time point. PBS and 
FITC-labeled HA or CS (0.5 mg mL−1) in PBS were used as negative and 
positive controls, respectively.
Swelling Behavior: The swelling behavior of foams was measured 
by recording their dry weight (Wd) followed by swelling in HA or CS 
(0.5 mg mL−1) in PBS for 24 h at 37 °C. The foams were then removed 
from solution at 2, 4, 6, 24, and 48 h post incubation, washed three 
times in PBS, and their wet weight (Ws) was recorded. The swelling ratio 
of the foams was calculated using Equation (1) and normalized to their 
swelling ratio in PBS without exogenous GAGs in the solution. 
−


 ×
w w
w
s d
d
Swelling ratio(%)=
( )
100
 
(1)
hMSC Culture: Bone marrow-derived hMSCs were purchased from 
PromoCell GmbH (Germany). hMSCs were seeded at 4000 cells per cm2 
in T225 flasks and cultured in mesenchymal stem cell growth medium 
(MSCGM) (PromoCell GmbH, Germany). hMSCs were incubated at 
37 °C in a 5% CO2 atmosphere and the medium was changed every 3 d. 
The cells were harvested at 80% confluency with trypsin–EDTA (0.025% 
(w/v)) in PBS, centrifuged, and subcultured in MSCGM. Passage 
6 hMSCs were used for all cell–material interaction experiments.
Cell Seeding and Culture: Foams were placed in 48-well plates coated 
with agarose (2% (w/v)) to prevent cells from adhering to the well 
surfaces. An aliquot (50 μL) of chondrogenic medium (high-glucose 
(4.5 g L−1) Dulbecco’s modified Eagle medium (DMEM; Invitrogen, UK) 
supplemented with dexamethasone (0.1 × 10−3 m), penicillin streptomycin 
(1% (v/v)), l-proline (50 μg mL−1), ascorbate-2-phosphate (50 μg mL−1), 
1× insulin–transferrin–selenium (ITS) Premix (BD Biosciences, UK), 
and TGF-β3 (Lonza, UK) (10 ng mL−1)) containing 1 × 106 hMSCs was 
injected into the foams and the cells were allowed to migrate and adhere 
to the foams for 30 min at 37 °C in a 5% CO2 atmosphere before slowly 
topping up the wells with chondrogenic medium. Foams were incubated 
for 6 weeks with the medium changed every 3 d.
Weight Change: The dry weight of each foam was measured over 
time in the absence of cells to evaluate their degradation. Foams 
were prepared as previously described and incubated in chondrogenic 
medium for 24 h at 37 °C in a 5% CO2 atmosphere. The foams were 
incubated in chondrogenic medium with exogenous MMPs (30 ng mL−1) 
at 37 °C in a 5% CO2 atmosphere for 1 week with medium changed 
and dry weight measurements taken daily. Percentage weight change 
was normalized to day 0. Degradation by recombinant human MMP1, 
MMP2, MMP7, and MMP13 (AnaSpec, USA) was tested against a 
negative control (chondrogenic medium alone) and a positive control 
(0.2 μg mL−1 proteinase K).
Cell-seeded foams were incubated in chondrogenic medium at 37 °C 
in a 5% CO2 atmosphere for 6 weeks, and dry weight measurements 
were taken after 0, 1, 3, 7, 14, 21, 28, and 42 d of culture. Percentage 
weight change corresponding to the cumulative effect of cell 
proliferation, cartilage-like matrix deposition, and foam degradation was 
normalized to day 0.
Cell Adhesion and Viability: hMSC-seeded foams were cultured for 0, 1, 
3, 7, 14, 21, 28, and 42 d. After the culture period, the foams were washed 
three times in PBS and analyzed for cell adhesion and viability. Cell viability 
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was qualitatively assessed with a LIVE/DEAD Viability/Cytotoxicity Kit 
(Molecular Probes, USA) according to the manufacturers’ instructions. 
Fluorescence confocal microscopy (Leica SP5 inverted microscope, 
Leica Microsystems) was used to visualize live (calcein; green) and dead 
(ethidium homodimer–1; red) cells. The metabolic activity of cells in 
the foams was quantified by the AlamarBlue assay (Serotec, USA). This 
assay is based on the fluorescent signal output produced by metabolically 
active cells. Measurements were made at 570 nm and 600 nm. Cell-free 
foams and empty wells were used as controls. All data were normalized 
to DNA content present at each time point.
DNA, sGAG, and Hydroxyproline Quantification: hMSC-seeded foams 
were cultured for 0, 1, 3, 7, 14, 21, 28, and 42 d. After the culture 
period, the constructs were washed three times in PBS and digested 
individually in papain digest solution (2.5 units papain per mL, cysteine 
HCl (5 × 10−3 m), EDTA (5 × 10−3 m), pH 7.4, in PBS) at 60 °C for 24 h. 
Papain digests were stored at −20 °C until further analysis. Digested 
samples were assayed for DNA content using the Quant–iT PicoGreen 
Kit (Invitrogen, USA) according to the manufacturers’ instructions. 
Measurements were made at 535 nm. The standard curve was generated 
with dsDNA (Invitrogen, USA).
Sulfated glycosaminoglycan (sGAG) content was quantified using the 
Blyscan Kit (Biocolor, UK) according to the manufacturers’ instructions. 
Measurements were made at 656 nm. The standard curve was generated 
with bovine trachea chondroitin sulfate A.
Total new, cell-derived collagen content was estimated by measuring 
the hydroxyproline content. Unlike mammalian collagens, bacterial 
collagens lack hydroxyproline, which enabled us to distinguish between 
the collagen in the foams and new collagen deposition by the hMSCs. 
Papain-digested samples were hydrolyzed in HCl (6 N) at 110 °C for 
18 h, then pH adjusted using NaOH (5.7 N). The hydroxyproline content 
of the hydrolysate was determined using the chloramine-T/Ehrlich’s 
reagent assay and the color change quantified spectrophotometrically at 
560 nm.[49,50] The standard curve was generated with L-hydroxyproline 
and a conversion factor of 10 was used to convert from hydroxyproline 
to total collagen content.
Histology and Immunohistochemistry: After 0 and 42 d of culture, 
hMSC-seeded foams were washed three times in PBS, fixed with 
paraformaldehyde (Electron Microscopy Sciences, USA) (4% (v/v)) for 30 
min at 4 °C, washed three times in PBS, permeabilized with Triton X-100 
(0.4% (v/v)) for 30 min, and washed again. Foams were flash frozen in 
OCT (Tissue-Tek, Fisher Scientific) and cross-sections were cryosectioned 
at a thickness of 10 μm. Sections were transferred to treated slides 
(Superfrost Plus, Thermo Scientific) and allowed to adhere for 24 h at 
4 °C. Slides were stained for deposited sGAG with alcian blue (AB; pH 2.5) 
and for cell nuclei and matrix with hematoxylin and eosin (H&E).
Immunohistochemical staining (IHC) was performed for collagen 
type I, collagen type II, collagen type X, aggrecan, and CD44 with rabbit IgG 
secondary antibody and PBS negative controls. Samples were pretreated 
with hydrogen peroxide (3%), an avidin and biotin blocking kit (Vector Labs, 
UK), and blocked with goat serum (5% (v/v)). Primary antibodies were 
incubated overnight at 1/200 in goat serum (5% (v/v)), followed by goat 
anti-rabbit secondary antibody labeled with HRP at 1:100 for 1 h, stained 
with a 3,3′-diaminobenzidine (DAB) kit (Vector Labs, UK) for 10 min, and 
counter-stained with hematoxylin. All stained sections were dehydrated, 
mounted with Histomount (Fisher Scientific, UK), and viewed on an 
Olympus BX51 microscope equipped with an Olympus DP70 camera.
Gene Expression Analysis: hMSC-seeded foams were cultured for 0, 1, 
3, 7, 14, 21, 28, and 42 d. After the culture period, the constructs were 
washed three times in PBS. Total RNA was isolated using a tissue ruptor 
(Qiagen, USA) to homogenize samples with RLT buffer after which 
QIAshredder columns (Qiagen, USA) and the RNeasy Mini Kit (Qiagen, 
USA) were used to extract the RNA according to the manufacturers’ 
instructions. QuantiTect Reverse Transcription Kit (Qiagen, USA) and 
QuantiTect SYBR Green PCR Kit (Qiagen, USA) were used to perform 
reverse transcription and quantitative PCR (qPCR), respectively. 
Thermocycling and SYBR Green detection were performed on a Corbett 
Rotorgene 6000 (Qiagen, USA) with extension at 72 °C and denaturing at 
95 °C. Annealing temperatures were primer specific. Data were analyzed 
using the ΔΔCt method.[51] The following primers were used: GAPDH 
(Quiagen, USA) (Forward 5′-TGGTATCGTGGAAGGACTCATGA-3′ 
and Reverse 5′-ATGCCAGTGAGCTTCCCGTTCAG-3′), 
COL1A1 (Forward 5′-CATTAGGGGTCACAATGGTC-3′ 
and Reverse 5′-TG GAG TTCCATTTTCACCAG-3′), COL2A1 
(Forward 5′-CATC CCACCCTCTCACAGTT-3′ and Reverse 
5′-GTCTCTGCCTTGACCCAAAG-3′), COL10A1 (Forward 5′-AATGCCT-
GTGTCTGCTTTTAC-3′ and Reverse 5′-ACAAGTAAAGATTCCAGTCCT-3′), 
CD44 (Forward 5′-CATCTACCCCAGCAACCCTA-3′ and Reverse 
5′-CTGTCTGTGCTGTGGGTGAT-3′), and ACAN (Forward 
5′-CACT GTTACCGCCACTTCCC-3′ and Reverse 5′-GACAT-
CGTTCCACTCGCCCT-3′) at an annealing temperature of 
60 °C, and SOX9 (Forward 5′-AACGCCGAGCTCAGCAAG-3′ and Reverse 
5′-ACGAACGGCCGCTTCTC-3′) at an annealing temperature of 62 °C.
Statistical Analysis: All cell-related experiments were repeated three 
times with hMSCs from different donors and with each donor having 
an intraexperimental sample size of 3. Data are presented as means 
± standard deviation (SD). Statistical significance was determined by 
performing analysis of variance (ANOVA) with Bonferroni correction and 
with a significance accepted at p value < 0.05.
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